Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Third time lucky for Lilly's solanezumab?

This article was originally published in Scrip

Executive Summary

Alzheimer’s disease is one of the most challenging therapeutic targets to be pursued in pharmaceutical R&D. While research into this disease therapy has been somewhat successful in terms of developing symptomatic therapies, there has been a track record of failures for disease-modifying candidates – such as bapineuzumab (Johnson & Johnson/Pfizer). Moreover, there is still plenty of deliberation among the scientific community over the actual pathogenesis of Alzheimer’s disease and the different approaches to targeting its complex underlying mechanisms. But, with significant revenue potential waiting to be mined, Eli Lilly is firmly betting on the beta-amyloid approach, thus taking a great risk in the hope of achieving the high returns that it needs in order to offset one of the largest patent-cliffs within its Big Pharma peer-set, says Datamonitor Healthcare analyst Higia Vassoler.

You may also be interested in...

Zytiga fallout: Stringent EU HTAs mean Dendreon may need 65-70% off Provenge

The European prostate cancer treatment space is characterized by economic austerity and strict reimbursement regulation. Nevertheless, Dendreon is preparing to launch Provenge in Europe in an attempt to counter the vaccine's disappointing US launch in April 2010. European health technology assessors have already blocked drugs which are more convenient and bear costs approximately one-third those of Provenge in the US. Adding those specific hurdles to the general economic environment for cancer drugs in Europe makes it likely that Dendreon will have to look for revenue growth elsewhere.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts